{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:23:59Z","timestamp":1777407839315,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Low-grade serous ovarian carcinoma (LGSOC) is a rare, treatment-resistant subtype of ovarian cancer characterized by peritoneal spread. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) delivers chemotherapy directly into the abdomen during serial laparoscopic surgeries, enabling repeated sampling of tumors for longitudinal analysis. Using single-nuclei RNA sequencing on 15 tumor samples across PIPAC cycles in two patients (a responder and a non-responder), we tracked molecular and cellular changes over time. Non-responder tumors showed upregulation of proliferation pathways (E2F, MYC, G2\/M), KRAS signaling, epithelial-mesenchymal transition, and unfolded protein response, correlating with resistance. Responder tumors exhibited downregulation of proliferation and stress pathways but activated alternative survival mechanisms (PI3K, Wnt\/\u03b2-catenin, Notch). Archetype analysis revealed dynamic shifts in metabolic and immune-related subpopulations in the responder tumors, while immunoprofiling showed greater immunosuppression in non-responder tumors. Despite the small cohort, these exploratory observations highlight tumor adaptation and underscore the need for multi-targeted therapies addressing proliferation, stress, survival, and immune evasion.<\/jats:p>","DOI":"10.1038\/s41698-025-01182-3","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T05:36:03Z","timestamp":1765690563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Divergent oncogenic signaling and immune microenvironment changes in low-grade serous ovarian cancer patients undergoing intraperitoneal chemotherapy"],"prefix":"10.1038","volume":"10","author":[{"given":"Isaac","family":"Bishara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick A.","family":"Cosgrove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumana","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colt A.","family":"Egelston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar Colunga","family":"Flores","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Ruel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul H.","family":"Frankel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan E.","family":"Yost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Cristea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Raoof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea H.","family":"Bild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aritro","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh H.","family":"Dellinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"1182_CR1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/01.pgp.0000101080.35393.16","volume":"23","author":"JD Seidman","year":"2004","unstructured":"Seidman, J. D. et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 23, 41\u201344 (2004).","journal-title":"Int. J. Gynecol. Pathol."},{"key":"1182_CR2","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1200\/JCO.2015.61.0873","volume":"33","author":"DM Gershenson","year":"2015","unstructured":"Gershenson, D. M. et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J. Clin. Oncol. 33, 2675\u20132682 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"1182_CR3","doi-asserted-by":"crossref","first-page":"i45","DOI":"10.1093\/annonc\/mdw085","volume":"27","author":"DM Gershenson","year":"2016","unstructured":"Gershenson, D. M. Low-grade serous carcinoma of the ovary or peritoneum. Ann. Oncol. 27(Suppl 1), i45\u2013i49 (2016).","journal-title":"Ann. Oncol."},{"key":"1182_CR4","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","volume":"95","author":"G Singer","year":"2003","unstructured":"Singer, G. et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl. Cancer Inst. 95, 484\u2013486 (2003).","journal-title":"J. Natl. Cancer Inst."},{"key":"1182_CR5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2023.04.011","volume":"174","author":"JP Thomson","year":"2023","unstructured":"Thomson, J. P. et al. Whole exome sequencing of low grade serous ovarian carcinoma identifies genomic events associated with clinical outcome. Gynecol. Oncol. 174, 157\u2013166 (2023).","journal-title":"Gynecol. Oncol."},{"key":"1182_CR6","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1200\/JCO.2015.61.4776","volume":"33","author":"AA Wright","year":"2015","unstructured":"Wright, A. A. et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J. Clin. Oncol. 33, 2841\u20132847 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1182_CR7","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","volume":"378","author":"WJ van Driel","year":"2018","unstructured":"van Driel, W. J. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med. 378, 230\u2013240 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1182_CR8","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1200\/JCO.2022.40.16_suppl.5524","volume":"40","author":"SP Somashekhar","year":"2022","unstructured":"Somashekhar, S. P. et al. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) versus intravenous chemotherapy in unresectable peritoneal metastases secondary to platinum-resistant ovarian cancer: Interim analysis of Indian randomized control trial. J. Clin. Oncol. 40, 5524\u20135524 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1182_CR9","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1245\/s10434-023-14648-0","volume":"31","author":"G Vizzielli","year":"2024","unstructured":"Vizzielli, G. et al. Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor: A single-institution experience (ID: PARROT trial). Ann. Surg. Oncol. 31, 1207\u20131216 (2024).","journal-title":"Ann. Surg. Oncol."},{"key":"1182_CR10","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1007\/s00404-024-07586-z","volume":"310","author":"M Pavone","year":"2024","unstructured":"Pavone, M. et al. Efficacy and safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in ovarian cancer: a systematic review of current evidence. Arch. Gynecol. Obstet. 310, 1845\u20131856 (2024).","journal-title":"Arch. Gynecol. Obstet."},{"key":"1182_CR11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/sajc.sajc_92_18","volume":"8","author":"SP Somashekhar","year":"2019","unstructured":"Somashekhar, S. P., Ashwin, K. R., Kumar, C. R., Rauthan, A. & Rakshit, S. H. Pressurized intraperitoneal aerosol chemotherapy procedure for nonresectable peritoneal carcinomatosis: first Indian study. South Asian J. Cancer 8, 27\u201330 (2019).","journal-title":"South Asian J. Cancer"},{"key":"1182_CR12","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-34627-5","volume":"13","author":"RL Hollis","year":"2023","unstructured":"Hollis, R. L. et al. Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma. Sci. Rep. 13, 7681 (2023).","journal-title":"Sci. Rep."},{"key":"1182_CR13","volume":"20","author":"K-K Wong","year":"2022","unstructured":"Wong, K.-K. et al. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors. J. Transl. Med. 20, 606 (2022).","journal-title":"J. Transl. Med."},{"key":"1182_CR14","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrc3800","volume":"14","author":"M Wang","year":"2014","unstructured":"Wang, M. & Kaufman, R. J. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat. Rev. Cancer 14, 581\u2013597 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"1182_CR15","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.12688\/f1000research.126337.1","volume":"11","author":"L Therachiyil","year":"2022","unstructured":"Therachiyil, L. et al. Role of RAS signaling in ovarian cancer. F1000Res 11, 1253 (2022).","journal-title":"F1000Res"},{"key":"1182_CR16","doi-asserted-by":"crossref","first-page":"620907","DOI":"10.3389\/fonc.2021.620907","volume":"11","author":"L Yin","year":"2021","unstructured":"Yin, L. et al. Heat shock protein 90 triggers multi-drug resistance of ovarian cancer via AKT\/GSK3\u03b2\/\u03b2-catenin signaling. Front. Oncol. 11, 620907 (2021).","journal-title":"Front. Oncol."},{"key":"1182_CR17","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1172\/JCI125963","volume":"129","author":"C Pan","year":"2019","unstructured":"Pan, C. et al. Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation. J. Clin. Invest. 129, 4110\u20134123 (2019).","journal-title":"J. Clin. Invest."},{"key":"1182_CR18","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1038\/sj.onc.1210289","volume":"26","author":"T Igarashi","year":"2007","unstructured":"Igarashi, T. et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 26, 4749\u20134760 (2007).","journal-title":"Oncogene"},{"key":"1182_CR19","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.4161\/cc.8.23.10086","volume":"8","author":"T Rzymski","year":"2009","unstructured":"Rzymski, T., Milani, M., Singleton, D. C. & Harris, A. L. Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8, 3838\u20133847 (2009).","journal-title":"Cell Cycle"},{"key":"1182_CR20","volume":"2","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Tumor evolution and chemoresistance in ovarian cancer. NPJ Precis. Oncol. 2, 20 (2018).","journal-title":"NPJ Precis. Oncol."},{"key":"1182_CR21","doi-asserted-by":"crossref","first-page":"7260","DOI":"10.18632\/oncotarget.2428","volume":"5","author":"SV Nuti","year":"2014","unstructured":"Nuti, S. V., Mor, G., Li, P. & Yin, G. TWIST and ovarian cancer stem cells: implications for chemoresistance and metastasis. Oncotarget 5, 7260\u20137271 (2014).","journal-title":"Oncotarget"},{"key":"1182_CR22","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41568-023-00581-7","volume":"23","author":"A Dart","year":"2023","unstructured":"Dart, A. EMT in chemoresistance. Nat. Rev. Cancer 23, 349 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"1182_CR23","doi-asserted-by":"crossref","first-page":"35231","DOI":"10.18632\/oncotarget.6159","volume":"6","author":"KN Thompson","year":"2015","unstructured":"Thompson, K. N. et al. The combinatorial activation of the PI3K and Ras\/MAPK pathways is sufficient for aggressive tumor formation, while individual pathway activation supports cell persistence. Oncotarget 6, 35231\u201335246 (2015).","journal-title":"Oncotarget"},{"key":"1182_CR24","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1158\/0008-5472.CAN-03-3853","volume":"64","author":"R Korah","year":"2004","unstructured":"Korah, R., Boots, M. & Wieder, R. Integrin alpha5beta1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res. 64, 4514\u20134522 (2004).","journal-title":"Cancer Res."},{"key":"1182_CR25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target. Ther. 6, 425 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1182_CR26","doi-asserted-by":"crossref","first-page":"22130","DOI":"10.1002\/jcp.28775","volume":"234","author":"S Bocchicchio","year":"2019","unstructured":"Bocchicchio, S., Tesone, M. & Irusta, G. Convergence of Wnt and Notch signaling controls ovarian cancer cell survival. J. Cell. Physiol. 234, 22130\u201322143 (2019).","journal-title":"J. Cell. Physiol."},{"key":"1182_CR27","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/0008-5472.CAN-21-4087","volume":"82","author":"AR Elhamamsy","year":"2022","unstructured":"Elhamamsy, A. R., Metge, B. J., Alsheikh, H. A., Shevde, L. A. & Samant, R. S. ribosome biogenesis: a central player in cancer metastasis and therapeutic resistance. Cancer Res. 82, 2344\u20132353 (2022).","journal-title":"Cancer Res."},{"key":"1182_CR28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/ijms18010210","volume":"18","author":"S Yan","year":"2017","unstructured":"Yan, S. et al. The potential of targeting ribosome biogenesis in high-grade serous ovarian cancer. Int. J. Mol. Sci. 18, 210 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"1182_CR29","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.trecan.2023.07.015","volume":"9","author":"JH Kang","year":"2023","unstructured":"Kang, J. H. & Zappasodi, R. Modulating Treg stability to improve cancer immunotherapy. Trends Cancer 9, 911\u2013927 (2023).","journal-title":"Trends Cancer"},{"key":"1182_CR30","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.3389\/fimmu.2019.02453","volume":"10","author":"CM Paluskievicz","year":"2019","unstructured":"Paluskievicz, C. M. et al. T regulatory cells and priming the suppressive tumor microenvironment. Front. Immunol. 10, 2453 (2019).","journal-title":"Front. Immunol."},{"key":"1182_CR31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13578-022-00823-5","volume":"12","author":"M Li","year":"2022","unstructured":"Li, M., He, L., Zhu, J., Zhang, P. & Liang, S. Targeting tumor-associated macrophages for cancer treatment. Cell Biosci. 12, 85 (2022).","journal-title":"Cell Biosci."},{"key":"1182_CR32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","volume":"399","author":"DM Gershenson","year":"2022","unstructured":"Gershenson, D. M. et al. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial. Lancet 399, 541\u2013553 (2022).","journal-title":"Lancet"},{"key":"1182_CR33","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1158\/0008-5472.CAN-20-2222","volume":"81","author":"R Shrestha","year":"2021","unstructured":"Shrestha, R. et al. Multiomics characterization of low-grade serous ovarian carcinoma identifies potential biomarkers of MEK inhibitor sensitivity and therapeutic vulnerability. Cancer Res. 81, 1681\u20131694 (2021).","journal-title":"Cancer Res."},{"key":"1182_CR34","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5732\/cjc.014.10289","volume":"34","author":"B Cheaib","year":"2015","unstructured":"Cheaib, B., Auguste, A. & Leary, A. The PI3K\/Akt\/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin. J. Cancer 34, 4\u201316 (2015).","journal-title":"Chin. J. Cancer"},{"key":"1182_CR35","volume":"12","author":"VHL Nguyen","year":"2019","unstructured":"Nguyen, V. H. L., Hough, R., Bernaudo, S. & Peng, C. Wnt\/\u03b2-catenin signalling in ovarian cancer: Insights into its hyperactivation and function in tumorigenesis. J. Ovarian Res. 12, 122 (2019).","journal-title":"J. Ovarian Res."},{"key":"1182_CR36","doi-asserted-by":"crossref","first-page":"23720","DOI":"10.18632\/oncotarget.4690","volume":"6","author":"AB Nagaraj","year":"2015","unstructured":"Nagaraj, A. B. et al. Critical role of Wnt\/\u03b2-catenin signaling in driving epithelial ovarian cancer platinum resistance. Oncotarget 6, 23720\u201323734 (2015).","journal-title":"Oncotarget"},{"key":"1182_CR37","doi-asserted-by":"crossref","first-page":"S282","DOI":"10.1016\/j.ygyno.2024.07.419","volume":"190","author":"R Grisham","year":"2024","unstructured":"Grisham, R. et al. A phase III, randomized trial evaluating avutometinib plus defactinib compared with investigator\u2019s choice of therapy among patients with recurrent low-grade serous ovarian cancer: GOG-3097\/ENGOT-OV81\/NCRI\/RAMP 301. Gynecol. Oncol. 190, S282\u2013S283 (2024).","journal-title":"Gynecol. Oncol."},{"key":"1182_CR38","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.1200\/JCO.2023.41.16_suppl.5515","volume":"41","author":"SN Banerjee","year":"2023","unstructured":"Banerjee, S. N. et al. Initial efficacy and safety results from ENGOT-ov60\/GOG-3052\/RAMP 201: a phase 2 study of avutometinib (VS-6766) \u00b1 defactinib in recurrent low-grade serous ovarian cancer (LGSOC). J. Clin. Oncol. 41, 5515\u20135515 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1182_CR39","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1200\/JCO.2022.40.16_suppl.5522","volume":"40","author":"LP Cobb","year":"2022","unstructured":"Cobb, L. P. et al. A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma. J. Clin. Oncol. 40, 5522\u20135522 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1182_CR40","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/s41586-019-1099-1","volume":"568","author":"Z Vrselja","year":"2019","unstructured":"Vrselja, Z. et al. Restoration of brain circulation and cellular functions hours post-mortem. Nature 568, 336\u2013343 (2019).","journal-title":"Nature"},{"key":"1182_CR41","volume":"8","author":"R Gao","year":"2017","unstructured":"Gao, R. et al. Nanogrid single-nucleus RNA sequencing reveals phenotypic diversity in breast cancer. Nat. Commun. 8, 228 (2017).","journal-title":"Nat. Commun."},{"key":"1182_CR42","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s43018-021-00215-7","volume":"2","author":"JI Griffiths","year":"2021","unstructured":"Griffiths, J. I. et al. Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4\/6 therapy. Nat. Cancer 2, 658\u2013671 (2021).","journal-title":"Nat. Cancer"},{"key":"1182_CR43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23171-3","volume":"12","author":"A Nath","year":"2021","unstructured":"Nath, A. et al. Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. Nat. Commun. 12, 3039 (2021).","journal-title":"Nat. Commun."},{"key":"1182_CR44","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.3390\/jcm13247507","volume":"13","author":"PA Cosgrove","year":"2024","unstructured":"Cosgrove, P. A. et al. Single-cell transcriptomics sheds light on tumor evolution: perspectives from City of Hope\u2019s clinical trial teams. J. Clin. Med. 13, 7507 (2024).","journal-title":"J. Clin. Med."},{"key":"1182_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03215-z","author":"J Klughammer","year":"2024","unstructured":"Klughammer, J. et al. A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03215-z (2024).","journal-title":"Nat. Med."},{"key":"1182_CR46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1681\/ASN.2018090912","volume":"30","author":"H Wu","year":"2019","unstructured":"Wu, H., Kirita, Y., Donnelly, E. L. & Humphreys, B. D. Advantages of single-nucleus over single-cell RNA sequencing of adult kidney: rare cell types and novel cell states revealed in fibrosis. J. Am. Soc. Nephrol. 30, 23\u201332 (2019).","journal-title":"J. Am. Soc. Nephrol."},{"key":"1182_CR47","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41591-020-0844-1","volume":"26","author":"M Slyper","year":"2020","unstructured":"Slyper, M. et al. A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat. Med. 26, 792\u2013802 (2020).","journal-title":"Nat. Med."},{"key":"1182_CR48","doi-asserted-by":"publisher","unstructured":"Jiang, A. et al. Isolated nuclei from frozen tissue are the superior source for single cell RNA-seq compared with whole cells. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.02.19.529150 (2023).","DOI":"10.1101\/2023.02.19.529150"},{"key":"1182_CR49","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/bioinformatics\/btw817","volume":"33","author":"X Chen","year":"2017","unstructured":"Chen, X. & Chang, J. T. Planning bioinformatics workflows using an expert system. Bioinformatics 33, 1210\u20131215 (2017).","journal-title":"Bioinformatics"},{"key":"1182_CR50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"1182_CR51","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","volume":"36","author":"A Butler","year":"2018","unstructured":"Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411\u2013420 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1182_CR52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"1182_CR53","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41587-020-00795-2","volume":"39","author":"R Gao","year":"2021","unstructured":"Gao, R. et al. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat. Biotechnol. 39, 599\u2013608 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1182_CR54","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: Open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"1182_CR55","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02554-5","volume":"9","author":"D Risso","year":"2018","unstructured":"Risso, D., Perraudeau, F., Gribkova, S., Dudoit, S. & Vert, J.-P. A general and flexible method for signal extraction from single-cell RNA-seq data. Nat. Commun. 9, 284 (2018).","journal-title":"Nat. Commun."},{"key":"1182_CR56","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"1182_CR57","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","volume":"462","author":"DA Barbie","year":"2009","unstructured":"Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108\u2013112 (2009).","journal-title":"Nature"},{"key":"1182_CR58","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc."}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01182-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01182-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01182-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T21:04:28Z","timestamp":1767474268000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-025-01182-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1182"],"URL":"https:\/\/doi.org\/10.1038\/s41698-025-01182-3","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.H.D. and M.R. received nebulizer devices from Reger free of cost for this PIPAC clinical trial. M.C. is an employee of Regeneron Pharmaceuticals Inc. and holds stock and\/or stock options in the company as part of their employment compensation. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1"}}